Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness

Nocturia Clinical Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01018225
• Other study ID #: CRC090001
• Status: Withdrawn
• Phase: Phase 4
• First received: November 20, 2009
• Last updated: April 12, 2016
• Start date: November 2009
• Est. completion date: July 2010

Study information

• Verified date: April 2016
• Source: Cognitive Research Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of darifenacin in the treatment of moderate to severe nocturia in patients with overactive bladder and who do not have non-urologic causes of nocturia.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years to 70 Years

Eligibility

Inclusion Criteria:

• Subject must be aged 21-70, inclusive.

• Subject mush have given written, personally signed and dated informed consent.

• Subject must be diagnosed with overactive bladder.

• Subject must have a nocturia frequency of greater than or equal to 3 episodes a night.

• Subject must be male or non-pregnant, non-lactating female who agrees to comply with applicable contraceptive requirements.

• Subject understands and is able, will a nd and likely to fully comply with study procedures and restrictions.

Exclusion Criteria:

• Subject has any concurrent chronic or acute illness or unstable medical condition either treated or untreated that could confound the results of safety assessments, increase risk to the subject or lead to difficulty complying with the protocol.

• The subject has a known or suspected allergy, hypersensitivity, or other medical contraindications to darifenacin (Enablex®) (or its components).

• The subject has concomitant diseases in which the use of anticholinergic drugs is contraindicated, e.g. urinary retention, bladder obstruction, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe hepatic impairment (Child Pugh C), severe ulcerative colitis, toxic megacolon, and patients who are at risk for these conditions.

• Subject is taking another drug which is considered to have significant anticholinergic activity.

• Use of drugs known to effect cognition, alertness or drowsiness, such as benzodiazepines, sedating antihistamines, opioids, or other sedative hypnotic drugs.

• Subject has moderate to severe obstructive sleep apnea (Apnea/Hypopnea Index = 15)

• Subject has a medical condition other than OAB that is the most likely cause of the subject's nocturia (e.g., primary sleep disorder, polydipsia, polyuria).

• Subject has taken another investigational drug or taken part in a clinical trial within the last 30 days prior to Screening.

• The female subject is pregnant or lactating.

• Subjects with a urine drug screen positive for stimulants, barbiturates, hallucinogens, opiates, cocaine, cannabis, or amphetamines

Study Design

N/A

Related Conditions & MeSH terms

• Nocturia

Intervention

Drug:
• darifenacin
7.5 or 15 mg darifenacin, once a day for 6 weeks
• Placebo
Placebo pill, once a day, for six weeks

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Cognitive Research Corporation	Novartis Pharmaceuticals